Cetera Investment Advisers Has $209,000 Stock Holdings in 10x Genomics $TXG

Cetera Investment Advisers raised its position in 10x Genomics (NASDAQ:TXG) by 20.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,991 shares of the company’s stock after acquiring an additional 4,093 shares during the period. Cetera Investment Advisers’ holdings in 10x Genomics were worth $209,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. RA Capital Management L.P. bought a new stake in shares of 10x Genomics in the 4th quarter valued at approximately $47,092,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of 10x Genomics by 10.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company’s stock valued at $30,394,000 after purchasing an additional 193,588 shares during the period. Voloridge Investment Management LLC lifted its stake in shares of 10x Genomics by 12.1% in the 4th quarter. Voloridge Investment Management LLC now owns 1,585,965 shares of the company’s stock valued at $22,774,000 after purchasing an additional 171,161 shares during the period. Two Sigma Investments LP raised its stake in 10x Genomics by 291.2% during the 4th quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company’s stock worth $18,948,000 after buying an additional 982,203 shares during the period. Finally, Two Sigma Advisers LP raised its stake in 10x Genomics by 240.6% during the 4th quarter. Two Sigma Advisers LP now owns 1,236,200 shares of the company’s stock worth $17,752,000 after buying an additional 873,200 shares during the period. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Price Performance

TXG stock opened at $14.30 on Friday. The stock has a market capitalization of $1.78 billion, a PE ratio of -20.43 and a beta of 2.03. The company’s 50-day moving average is $12.59 and its 200-day moving average is $10.68. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $24.76.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.63. The business had revenue of $172.91 million for the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. On average, analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TXG has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft set a $14.00 target price on 10x Genomics and gave the company a “hold” rating in a research report on Friday, August 8th. Stephens reaffirmed an “overweight” rating and issued a $14.00 target price on shares of 10x Genomics in a research report on Thursday, May 15th. Canaccord Genuity Group set a $16.00 price target on 10x Genomics in a report on Monday, August 11th. Wall Street Zen raised 10x Genomics from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Morgan Stanley cut their price target on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Tuesday, August 12th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $13.54.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.